Foundayo

What is Foundayo?

Foundayo is a prescription oral medication containing orforglipron, a first-in-class non-peptide small-molecule GLP-1 receptor agonist manufactured by Eli Lilly and Company. The FDA approved Foundayo on April 1, 2026, under new drug application number 220934 for chronic weight management in adults. Foundayo represents a landmark development in the GLP-1 class — all previous GLP-1 receptor agonists, including semaglutide, liraglutide, tirzepatide, dulaglutide, and exenatide, are peptides that require either injection or (in the case of Rybelsus) strict empty-stomach oral dosing because peptides are vulnerable to stomach acid and gastrointestinal degradation. Orforglipron is a small-molecule compound chemically engineered to bind the GLP-1 receptor with high affinity while also being orally bioavailable without food or water restrictions. This eliminates the need for injection and the complex pre-meal administration protocol of Rybelsus, offering a patient experience closer to typical daily oral medications. Foundayo is available in 3 mg, 6 mg, 12 mg, 24 mg, and 36 mg tablets.

How Foundayo works

Foundayo works by activating the same GLP-1 receptor as peptide-based GLP-1 agonists, but through an entirely different chemical approach. Orforglipron is a small organic molecule — not a peptide — that binds the GLP-1 receptor with high affinity and stimulates the same downstream signaling cascade. Once receptor activation occurs, the metabolic effects are identical to peptide GLP-1 agonists: glucose-dependent insulin secretion from pancreatic beta cells, suppression of glucagon, slower gastric emptying, and reduced appetite through central nervous system pathways. The practical innovation is absorption. Peptide drugs are readily degraded by stomach acid, digestive enzymes, and the intestinal lining, which is why Rybelsus requires a strict empty-stomach protocol and still achieves only about 1 percent bioavailability. Orforglipron's small-molecule structure is chemically stable through the digestive tract, absorbed through the gut wall without special delivery systems, and reaches systemic circulation reliably whether taken with or without food. This dramatically simplifies patient administration and opens GLP-1 therapy to patients who cannot or will not inject.

Who Foundayo is for

Foundayo is FDA-approved for chronic weight management in adults:

• Adults with obesity (BMI ≥ 30 kg/m²) — as an adjunct to reduced-calorie diet and increased physical activity.
• Adults with overweight (BMI ≥ 27 kg/m²) who also have at least one weight-related condition such as type 2 diabetes, hypertension, high cholesterol, or obstructive sleep apnea.

Foundayo is a particularly valuable option for patients who:

• Have a needle phobia or strongly prefer oral to injectable therapy
• Cannot reliably execute Rybelsus's strict empty-stomach administration protocol
• Want the convenience of a standard daily oral medication schedule
• Have tried injectable GLP-1 agents and found administration burdensome

Before prescribing Foundayo, your clinician will evaluate BMI, comorbidities, previous weight-management attempts, kidney function, history of pancreatitis or gallbladder disease, any personal or family history of medullary thyroid carcinoma or MEN 2, and insurance coverage. Foundayo is not FDA-approved for type 2 diabetes on its own (though diabetes trials are underway and a diabetes indication is anticipated), use during pregnancy or breastfeeding, or pediatric patients under 18. As a brand-new medication, insurance coverage is still developing and prior authorization is universal at this stage.

How to take Foundayo

Foundayo is administered as one tablet once daily, at any time of day, with or without food. No empty-stomach protocol is required. Swallow the tablet whole with water; do not split, crush, or chew. Most patients take Foundayo at the same time each day — many find mornings with breakfast coffee easiest — and set a recurring reminder to build the habit.

The titration schedule steps up at four-week intervals. Start at 3 mg once daily for four weeks as a starter dose (not fully therapeutic — its purpose is to let the body adjust and reduce early gastrointestinal side effects). After four weeks, increase to 6 mg daily for four weeks. Then advance to 12 mg daily as the first full maintenance dose. If additional weight loss is desired, the dose can be increased to 24 mg daily after four weeks at 12 mg, and ultimately to 36 mg daily (the maximum approved dose) after four weeks at 24 mg. Your prescriber may hold you at a lower dose if you achieve adequate weight loss or if side effects are bothersome.

If you miss a dose, take it as soon as you remember on the same day. If you do not remember until the next day, skip the missed dose and resume your regular schedule — do not take two doses in one day to make up for a missed one. If you miss three or more consecutive doses, contact your prescriber; you may need to restart titration at a lower dose. Store Foundayo tablets in the original bottle at room temperature (59°F to 86°F / 15-30°C) with the lid tightly closed. No refrigeration is needed, which is a significant logistic advantage over injectable GLP-1 agents.

Side effects of Foundayo

Foundayo's side-effect profile is qualitatively similar to peptide GLP-1 agonists — predominantly gastrointestinal, most prominent during titration — but intensities vary because of the different pharmacokinetic profile produced by oral small-molecule dosing. All frequencies below come from the ATTAIN clinical trial program pooled data in the FDA prescribing information.

Common side effects (worst during titration, typically improving over 2 to 3 months):

• Nausea — reported in 21 to 27 percent of patients depending on dose, peaking in the first weeks after each increase
• Diarrhea — 15 to 20 percent
• Vomiting — 10 to 16 percent, more frequent at higher doses
• Constipation — 8 to 14 percent
• Indigestion/dyspepsia — 6 to 10 percent
• Abdominal pain — 5 to 9 percent
• Headache — 5 to 8 percent
• Fatigue — 4 to 7 percent
• Hair loss — 3 to 5 percent, associated with rapid weight loss rather than direct drug effect

Less common but serious adverse events requiring prompt medical attention:

• Acute pancreatitis (less than 0.5 percent) — severe, persistent upper abdominal pain radiating to the back
• Gallbladder events (cholelithiasis, cholecystitis) — risk rises with any rapid weight loss
• Acute kidney injury — secondary to dehydration from persistent GI effects
• Diabetic retinopathy complications — rapid improvement in glycemia may temporarily worsen pre-existing retinopathy in patients with concurrent type 2 diabetes
• Serious allergic reactions — anaphylaxis and angioedema have been reported
• Hypoglycemia — rare on Foundayo alone; risk rises when combined with insulin or sulfonylureas in patients with concurrent diabetes

Management strategies — pause titration before advancing if side effects are severe, eat smaller meals more frequently, avoid high-fat or very spicy foods during the first weeks at each new dose, stay well hydrated, and limit alcohol. Contact your prescriber for severe abdominal pain, persistent vomiting, signs of dehydration, vision changes, or any rapid new symptom.

Who should not take Foundayo

Foundayo is contraindicated for patients with any of the following:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to orforglipron or any component of the tablet

Boxed warning: Orforglipron produced thyroid C-cell tumors in rodent studies. Whether this risk extends to humans is unknown. Patients should be counseled to report any persistent neck mass, difficulty swallowing, shortness of breath, or unexplained hoarseness to their prescriber.

Additional caution is appropriate for patients with a history of pancreatitis, severe gastroparesis or other significant gastrointestinal motility disorder, significant kidney impairment, pre-existing diabetic retinopathy, pregnancy or plans to become pregnant (orforglipron's half-life and placental transfer characteristics are still being characterized in real-world use), or breastfeeding. Because Foundayo slows gastric emptying, the absorption of other orally administered medications may be affected. As a brand-new drug, the full profile of clinically important drug-drug interactions is still being established through post-marketing surveillance — inform your pharmacist of every medication and supplement you take. Concurrent use with other GLP-1 receptor agonists (Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Victoza, Saxenda, Byetta, Bydureon) is not recommended.

What to expect on Foundayo

The Foundayo experience combines the appetite-suppressing benefits of GLP-1 therapy with the convenience of a standard daily oral medication.

Week 1 to week 4 (3 mg starter dose). Minimal expected weight change during this phase. Some appetite reduction may be noticeable within the first two weeks. GI side effects are typically concentrated in the first days after each new dose and resolve as the body adapts.

Month 2 to month 3 (6 mg and 12 mg titration). Appetite suppression builds noticeably. Weight loss averages 3 to 5 kg during this phase as patients transition to the first full maintenance dose.

Month 3 to month 6 (12 mg maintenance or higher). This is the period of steepest weight loss. In the ATTAIN-1 trial, patients on orforglipron 36 mg daily lost an average of 7 to 8 percent of baseline body weight by month 6. Patients who advance to 24 mg or 36 mg see progressively greater benefit. Many prescribers maintain patients at 12 mg if adequate weight loss is achieved without advancing.

Month 6 to 18 months. Weight loss continues to accumulate at a decelerating rate. At 72 weeks in ATTAIN-1, mean weight loss was approximately 12.4 percent of baseline body weight on the 36 mg dose. This is meaningful but notably less than the 16.9 percent produced by Wegovy 2.4 mg or the 22.5 percent produced by Zepbound 15 mg. For many patients, the convenience of oral dosing outweighs the modest efficacy difference.

Beyond 18 months and long-term. Patients who continue Foundayo typically sustain their weight loss. Discontinuation produces weight regain over 6 to 12 months similar to other GLP-1 agents. Your prescriber will schedule follow-up every three to six months to monitor weight, cardiometabolic labs, kidney function, and tolerability. Long-term data on Foundayo will accumulate over the coming years as the drug is new to market.

Foundayo cost and coverage

The list price of Foundayo is approximately $1,086 per 30-tablet supply before insurance, priced comparably to other branded GLP-1 agents on a monthly basis. As a newly launched medication, there is no generic version; Eli Lilly holds patent protection blocking generic competition for many years.

What you actually pay depends heavily on coverage — and because Foundayo is new, coverage is still evolving:

• Commercial insurance for obesity: Coverage is inconsistent in the early months post-launch. Plans that cover Wegovy, Zepbound, or Saxenda for obesity are likely to add Foundayo to their formularies over time, though initial prior-authorization requirements may be strict. Patients switching from another GLP-1 agent may need to document inadequate response or intolerance.
• Medicare Part D: Does not currently cover Foundayo for weight loss alone under the federal law excluding weight-loss medications from Part D.
• Medicaid: Coverage varies dramatically by state and is still developing for this new product.
• Manufacturer savings: Eli Lilly offers a Foundayo savings card for eligible commercially-insured patients; terms at launch include copays as low as $25 per month for up to 12 prescriptions. Not available to Medicare or Medicaid beneficiaries.
• LillyDirect: Eli Lilly's direct-to-consumer pharmacy will likely offer Foundayo with self-pay pricing as uptake builds.

Check your specific plan's coverage, the current Eli Lilly savings program, and LillyDirect before filling — coverage for this new oral GLP-1 will change rapidly in the coming months as insurers evaluate the product and patient demand increases.